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Abstract: The primary function of the female ovary is the production of a mature and viable oocyte capable of fertilization 
and subsequent embryo development and implantation. At birth, the ovary contains a ﬁ  nite number of oocytes available for 
folliculogenesis. This ﬁ  nite number of available oocytes is termed “the ovarian reserve”. The determination of ovarian 
reserve is important in the assessment and treatment of infertility. As the ovary ages, the ovarian reserve will decline. Infer-
tility affects approximately 15%–20% of reproductive aged couples. The most commonly used biomarker assay to assess 
ovarian reserve is the measurement of follicle stimulating hormone (FSH) on day 3 of the menstrual cycle. However, anti-
müllerian hormone and inhibin-B are other biomarkers of ovarian reserve that are gaining in popularity since they provide 
direct determination of ovarian status, whereas day 3 FSH is an indirect measurement. This review examines the physical 
tools and the hormone biomarkers used to evaluate ovarian reserve.
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Introduction
The primary function of the female ovary is the production of a mature and viable oocyte capable of 
fertilization and subsequent embryo development and implantation. At birth, the ovary contains a ﬁ  nite 
number of oocytes available for folliculogenesis. This ﬁ  nite number of available oocytes is termed “the 
ovarian reserve”. The determination of ovarian reserve is important in the assessment and treatment of 
infertility. As the ovary ages, the ovarian reserve will decline.
Ovarian reserve (OR) refers to the number and quality of oocytes that, at any given age, are available 
to produce a dominant follicle late in the follicular phase of the menstrual cycle. By estimating the OR, 
a prediction of the remaining reproductive lifetime could be assessed as well as the likely success of 
assisted reproductive techniques (ART) such as in vitro fertilization (IVF) (Baird et al. 2005). None of 
the OR tests directly measures the total number of actual oocytes. Rather, it is assumed that the number 
of recruitable and developing follicles (pre-antral and antral) is directly related to the total oocyte pool. 
During fetal life the ovaries are endowed with the entire stock of follicles (oocytes surrounded by ovar-
ian granulosa cells) that will serve a woman’s reproductive life. Because the number of quality oocytes 
available for recruitment during folliculogenesis changes markedly during a woman’s lifetime, the 
tendency is for OR physical evaluation tests to inaccurately estimate the total pool of “good-viable” 
oocytes. This review will look at the physical tools utilized to determine ovarian reserve.
Infertility affects approximately 15%–20% of reproductive aged couples. The most commonly used 
biomarker test to assess ovarian reserve is the measurement of day 3 follicle stimulating hormone (FSH); 
this blood test determines the level of FSH on day 3 of the menstrual cycle. Cycle day 3 is the preferred 
testing day due to the expected low level of estradiol, which in turn affects FSH levels via negative 
feedback control. Therefore, Day-3 FSH levels would be expected to be low, a higher than normal day-3 
FSH level would indicate a diminished ovarian reserve. However, this day still requires standardization 
to ensure reproducibility. Typically, Day-3 FSH and estradiol are both measured. However, other blood 
tests (antimüllerian hormone and, or inhibin-B) are gaining popularity since they provide more direct 
determination of ovarian status, whereas Day-3 FSH and estradiol are indirect measurements. This 
review will look at the aforementioned hormones as biomarkers of ovarian reserve.
Overview of Reproductive Endocrinology
From the hypothalamus, gonadotropin-releasing hormone (GnRH) acts upon the anterior pituitary to 
produce both FSH and luteinizing hormone (LH) both of which target the ovary in females. FSH is 260
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responsible for follicular recruitment and growth 
and for estrogen (mostly β-estradiol) conversion 
from androgens during folliculogenesis. Estrogens 
(e.g. estradiol, E2) are the primary hormones that 
provide negative feedback to the hypothalamus 
and anterior pituitary to inhibit FSH and LH secre-
tion. Granulosa cells are the target cells within the 
ovary for FSH activity. LH is responsible for ﬁ  nal 
follicular and oocyte maturation, subsequent ovu-
lation, and corpus luteum (CL) formation. During 
folliculogenesis, LH acts upon the ovarian theca 
cells to produce androgens. Following ovulation, 
LH will promote estrogen and progesterone secre-
tion by the CL. In addition to steroidal hormones, 
the ovary (i.e. granulosa cells) also produces a 
number of peptide hormones of the transforming 
growth factor (TGF)-β/activin superfamily. These 
peptides hormones may include relaxin, inhibin A, 
inhibin B, activin, follistatin and antimüllerian 
hormone (AMH) also called Müllerian inhibiting 
substance (MIS). For the purpose of this review, 
we will refer this peptide hormone as AMH.
The actions of activin include granulosa cell 
proliferation, upregulation of FSH and LH recep-
tor expression, enhancement of aromatase activity 
and subsequent estradiol production, suppression 
of androgen production, increased production of 
inhibins and follistatin and the enhancement of 
oocyte developmental competence. The primary 
action of follistatin is to bind to and neutralize 
activin.
Inhibin consists of two distinct chains, or sub-
units (alpha and beta), linked together. Inhibin A 
consists of the alpha-subunit and beta A-subunit. 
Inhibin B consists of the alpha-subunit and beta 
B-subunit. Only the dimeric forms of the molecule, 
containing both the alpha and beta subunits, are 
bioactive, although the free subunit forms exist in 
circulation. Inhibins are secreted by ovarian 
granulosa cells in females and by testicular Sertoli 
cells in males. Both inhibin A and inhibin B are 
produced in females, but in males inhibin B is the 
major circulating inhibin. Both inhibins suppress 
FSH secretion from the pituitary. During the men-
strual cycle and early pregnancy, inhibin A is 
produced by the CL. At the onset of menstruation 
during the early follicular phase, very low levels 
of inhibin A are detected. Levels of inhibin A 
increase dramatically in the late follicular phase 
and peaks in mid-luteal phase. The primary role of 
inhibin B appears to be in the regulation of 
folliculogenesis via a negative feedback on the 
production of FSH. Levels of inhibin B increase 
dramatically during folliculogenesis and are 
maximized just prior to ovulation.
AMH is produced by the Sertoli cells of the 
testis in the male and exclusively by ovarian 
granulosa cells of preantral follicles in the adult 
female. During embryonic development in males, 
secretion of AMH from testicular Sertoli cells is 
essential for the regression of the Müllerian ducts, 
and thus the normal development of the male repro-
ductive tract. The Müllerian ducts are the primor-
dium for the uterus, Fallopian tubes and upper 
vagina in the female. In the male, secretion of AMH 
by the Sertoli cells commences during embryogen-
esis and continues throughout life. Levels drop 
following puberty, decreasing slowly to a relatively 
low post-puberty value. In the female, serum AMH 
is undetectable until the onset of puberty. AMH is 
produced in a wide range of follicles from primary 
to early antral stages of folliculogenesis. The role 
of AMH is to modulate primordial follicle recruit-
ment and to inhibit cyclic follicle recruitment for 
folliculogenesis, primarily by inhibiting the action 
of FSH on follicle growth and selection. AMH 
levels are maintained at relatively low levels until 
menopause, at which time AMH progressively 
decreases again to undetectable levels.
Ovarian Reserve and Physical 
Testing
Ovarian reserve (OR) declines 
during the aging process
Although a decline in OR accompanies chronological 
aging, acceleration in this process appears to occur 
in a subset of pre-menopausal women. This is 
evidenced by suboptimal responses to ovarian 
stimulation attempts, as seen in a proportion of 
younger women undergoing treatments for infertility 
(de Boer et al. 2002; de Boer et al. 2003) and by the 
recent recognition that this subset of women may 
be destined for transition into menopause at a 
younger age (Lawson et al. 2003).
The determination of both the quantity and 
quality of the follicular pool may allow the predic-
tion of women who may under-respond or over-
respond to controlled ovarian hyperstimulation 
protocols in ART programs (Bukulmez and Arici, 
2004; Chang et al. 1998; Frattarelli et al. 2003; 
Bancsi et al. 2002; Vladimirov et al. 2005).261
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Physical tools used to assess OR
Ultrasonography (US) may be a useful tool in 
evaluating current ovarian function. During the 
early follicular phase of the menstrual cycle, the 
measurement of the ovarian volume (Lass et al. 
1997), the mean ovarian diameter (MOD) 
(Frattarelli et al. 2000), the antral follicle count 
(AFC) (Ruess et al. 1996), and the ovarian stromal 
blood ﬂ  ow with color Doppler (Engmann et al. 
1999; Zaidi et al. 1996) are all physical evaluation 
techniques for ovarian reserve prediction.
Ovarian volume and AFC values can be useful 
indicators of menopausal status (Flaws et al. 2001). 
Erdem et al. suggest that transvaginal ultrasonog-
raphy (TVS) rather than hormonal parameters is 
the preferred method for OR determination, as TVS 
assessment of ovarian volume and the AFC confer 
a stronger correlation with chronological aging 
than Day 3 FSH level indices and aging (Erdem 
et al. 2003).
The use of sonographic methods are somewhat 
limited, however, as they cannot predict future 
fertility. Rather, US can only predict current fertil-
ity or the ovarian response to IVF treatment. Until 
the very late stages of reproductive aging, most 
sonographic cycle characteristics in populations 
with proven fertility remain “normal” (te Velde and 
Pearson, 2002). Only at a mean age of approxi-
mately 46 to 48 years do normal menstrual cycle 
characteristics tend to disappear (te Velde and 
Pearson, 2002; Giacobbe et al. 2004).
In younger women, sonographic methods may 
be only a fertility snapshot during one menstrual 
cycle, as cycle-to-cycle consistency of both the 
AFC and ovarian volume have been demonstrated 
to be signiﬁ  cantly variable in younger sub-fertile 
women, with more variation observed in the AFC 
of younger infertile patients (Elter et al. 2005). 
Hence, a low AFC in a young, sub-fertile ovulatory 
woman should be interpreted cautiously, as a low 
AFC may not reﬂ  ect poor ovarian reserve.
Ovarian volume measurements
The ovarian volume in terms of total ovarian vol-
ume, volume of the smallest ovary and mean ovar-
ian volume, measured by TVS, were reported to 
correlate with response to controlled ovarian 
hyperstimulation (Lass et al. 1997; Flaws et al. 
2001; Sharara and McClamrock, 1999; Syrop et al. 
1999). In women where either ovary is small (less 
than three cm
3), the IVF cancellation rate was 
higher (Sharara and McClamrock, 1999). Single 
ovarian dimensions were shown to be a reliable 
predictor of declining OR status in pre-menopausal 
infertile women (Bowen et al. 2007) and in ovarian 
responsiveness during ART cycles (Frattarelli et al. 
2000; Frattarelli et al. 2002). The magnitude of this 
association was most robust for the ovarian width 
measurement (Bowen et al. 2007).
Some studies detected a signiﬁ  cant negative 
correlation between age of infertile women and 
ovarian volume by two-dimensional US (Syrop 
et al. 1999) and by three-dimensional US (Kupesic 
et al. 2003); other studies could not demonstrate 
such a correlation (Sharara and McClamrock, 
1999; Syrop et al. 1995). In fact, in a family 
Table 1. Comparison of the different physical tools to assess ovarian reserve.
Physical measurement tool Advantages Disadvantages
Ovarian volume Conﬁ  rms menopausal status 
reliable predictor of declining OR 
status independent of advancing 
age
Signiﬁ  cant changes in ovarian volume not 
discernable during end of reproductive years
Highly variable in younger infertile patients
Antral follicle count Consistent correlation to the 
age-related decline of reproduc-
tive capacity
There is no signiﬁ  cant difference 
between right-sided and left-
sided antral follicle counts within 
the same individual
The AFC is a useful prediction 
tool for poor IVF response or 
hyper IVF response
Performance for predicting failure to achieve 
pregnancy is poor 
Highly variable in younger infertile patients
AMH may be a better/equivalent predictor of 
age-related decline of reproductive capacity
Ovarian stromal blood ﬂ  ow 
velocity
Results are highly predictive of 
ovarian responsiveness
Results do not always correlate with 
advancing age 262
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planning clinic population of healthy women aged 
14–45 years, ovarian volume was shown not to be 
related to age (Christensen et al. 1997). Additional 
studies have demonstrated that a progressive 
decrease in ovarian volume correlated to aging is 
more discernable during post-menopause and not 
during the reproductive age, suggesting that ovar-
ian volume should not be utilized as a stand-alone 
OR test (Tepper et al. 1995; Ng, 2003 #80).
Antral follicle count measurements
The antral follicle count (AFC) is deﬁ  ned as the 
number of follicles smaller than 10 mm in diameter 
detected by TVS in the early follicular phase. The 
AFC has been shown to be a predictor of the num-
ber of oocytes retrieved in controlled ovarian 
hyperstimulation protocols (Tomas et al. 1997), 
the cancellation rates in IVF (Frattarelli et al. 2000; 
Tomas et al. 1997), and for predicting pregnancy 
loss in IVF pregnancies (Elter et al. 2005). The 
AFC has also been show to be a predictor of the 
number of immature oocytes retrieved for in vitro 
maturation (IVM) (Tan et al. 2002). There is no 
signiﬁ  cant difference between right-sided and left-
sided antral follicle counts within the same indi-
vidual (Chow et al. 2004). The AFC was shown to 
be a superior, or at least an equivalent, prediction 
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Figure 1. Schematic of the reproductive endocrinology in the female. Please see notations within the Figure for detailed description of the 
relationships between the hormones.263
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tool for poor IVF response (Hendriks et al. 2007; 
Kwee et al. 2007) or hyper IVF response (Kwee 
et al. 2007) when compared to ovarian volume 
measurement and complex endocrine challenge 
tests. Furthermore, the AFC has been established 
to be equally as useful as AMH in OR status 
determination and/or ovarian responsiveness 
(Muttukrishna et al. 2005; Nardo et al. 2007).
Reproducibility/reliability of the AFC 
measurement
The relationship between reproductive age and 
AFC and the reproducibility of AFC in regularly 
cycling women has been investigated by a number 
of different groups. Healthy female volunteers with 
proven, normal fertility and regular menstrual 
cycles were studied; and out of all parameters 
tested, the number of antral follicles has the closest 
association with chronological age (Scheffer et al. 
2003). Chinese women with proven fertility were 
evaluated; and among many ovarian reserve tests, 
only the AFC demonstrated the best correlation 
with women’s age (Ng et al. 2003).
Women undergoing their ﬁ  rst IVF cycle were 
evaluated with a battery of tests to compare several 
basal ovarian reserve markers (Bancsi et al. 2002). 
Measurements were performed to determine the 
number of antral follicles, total ovarian volume, 
basal FSH, E2, and Inhibin B on cycle day 3. The 
AFC was the best single predictor for poor ovarian 
response (Bancsi et al. 2002). Further work by the 
same group demonstrated that a single AFC is a 
good predictor of poor ovarian response in IVF, 
and that the clinical relevance of a second AFC 
during a subsequent cycle is of limited value 
(Bancsi et al. 2004).
In another study, the AFC was obtained in 
regularly cycling fertile women and was evaluated 
by cohort comparison for predicted distribution of 
age at reproductive events, such as the ages at last 
childbirth and at menopause (Broekmans et al. 
2004). Distribution of the observed ages at last 
childbirth and ages at menopause were obtained 
from the BALSAC (Bouchard et al. 1989) 
demographic database and the Prospect-EPIC 
(Riboli et al. 2002) study, respectively. This data 
comparison demonstrated that the link between 
declining AFCs and reproductively signiﬁ  cant 
events like loss of natural fertility and menopause 
is strengthened by the high degree of similarity 
among the predicted and observed age distributions 
(Broekmans et al. 2004). The study authors do 
point out, however, that there may be marginal 
clinical utility, except in the case of women who 
have low AFCs for their age.
In a new and rather intriguing study, a number 
of ovarian reserve tests were performed, such as 
AFC and an endocrine test panel, on sub-fertile, 
ovulatory patients (Haadsma et al. 2007). The 
study demonstrated that the number of pre-antral 
or small antral follicles (2–6 mm) declined with 
age and the number of larger follicles (7–10 mm) 
remained constant, suggesting that the number of 
small AFCs represents the functional OR (Haadsma 
et al. 2007).
The performance of the AFC for predicting 
failure to achieve pregnancy is poor (Bancsi et al. 
2002; Ng et al. 2003; Hendriks et al. 2005). While 
the AFC determines the number of oocytes, a 
clinically relevant outcome, such a pregnancy or 
live birth, is dependent on oocyte quality as well 
as quantity.
The ovarian volume, AFC, vascularization 
index, ﬂ  ow index, and vascularization-ﬂ  ow index 
were determined by 3-D Power Doppler Angiog-
raphy (PDA) indices, and all were shown to have 
excellent intra-observer and inter-observer repro-
ducibility (Merce et al. 2005). Further, the ovary 
functional stage (basal after pituitary suppression 
or stimulated after gonadotropin treatment) does 
not modify the reliability of any of these measure-
ments (Merce et al. 2005). Thus, 3-D US and PDA 
offer the advantage of evaluating all parameters in 
a single US examination, thereby improving the 
clinical evaluation of ovarian parameters. In addi-
tion, ovarian images captured by 3-D sonography 
can be stored and evaluated later, thereby uncou-
pling the need to analyze the data during ovarian 
examination (Scheffer et al. 2002).
Biomarkers: endocrine testing
Biomarkers are desirable for assessing fertility 
because of the minimal invasiveness of blood col-
lection in comparison to other procedures, reﬂ  ec-
tion of internal function, speed of analysis and 
reasonable cost. The “magic bullet” biomarker for 
ovarian reserve has yet to be clearly deﬁ  ned, yet. 
However many biomarkers do provide signiﬁ  cant 
insight as to ovarian reserve status. With the imple-
mentation of better testing methods and discovery 
of new biomarkers more options will be available. 
There are a few newly recognized biomarkers that 264
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look extremely promising, including AMH and 
inhibin-B.
There are both indirect and direct measures of 
ovarian reserve. Indirect measures include day 3 
follicular stimulating hormone (FSH), estradiol, 
and the FSH:LH ratios. These biomarkers are 
considered indirect measures, as they require 
stimulation from either a feedback inhibition or a 
stimulation loop. Essentially these biomarkers rely 
on the production of other hormones. Inhibin B 
and AMH are examples of direct measures of ovar-
ian reserve as these hormones are produced during 
speciﬁ  c stages of follicular development, rather 
than by follicular stimulation. These two biomark-
ers have recently been receiving additional visibil-
ity with the development of more robust and 
reliable laboratory methods. This makes these 
biomarker assays additionally appealing and fur-
ther reproducible for laboratories. In addition to 
indirect and direct measures, there are a couple of 
stimulation tests that have been developed and are 
frequently used to ascertain or estimate ovarian 
reserve. These stimulation tests require drug expo-
sure, baseline measurements, and follow-up mea-
surements of the biomarkers, such as FSH.
Indirect Measures
Day 3 FSH
Day 3 FSH is believed to represent the “basal” 
level or non-suppressed level of FSH through 
ovarian feedback to the pituitary (Barnhart and 
Osheroff, 1998). Day 3 FSH has been credited with 
being a biomarker for ovarian reserve since the late 
1980s, as it provides a glimpse of how well the 
hypothalamic-pituitary-gonadal axis is functioning 
(Barnhart and Osheroff, 1998). As women and their 
follicles age, the amount of FSH secreted increases 
due to the lack of responsiveness of the ovary 
(Perloe et al. 2000). As day 3 FSH levels climb, it 
is indicative of a diminished ovarian reserve. In 
fact, ﬂ  uctuation between cycles of day 3 FSH 
levels is important to note as it may be reﬂ  ective 
of the decline in ovarian reserve (Perloe et al. 
2000).
Monitoring day 3 FSH levels may not be the 
best option for monitoring ovarian reserve, but it 
is the most widely recognized OR biomarker and 
it does provide some insight. Testing is available 
on multiple automated platforms and thus is rela-
tively fast, inexpensive, and reproducible. FSH is 
proven to increase with the age of follicles and that 
increase is more dramatic and earlier than that of 
LH (Perloe et al. 2000). Historically, FSH has been 
the biomarker of choice; it is well studied, docu-
mented, and validated which provides a level of 
comfort to physicians (Sharara et al. 1998).
It is important to recognize some of the issues 
with using FSH as a biomarker for OR testing. 
Between cycle ﬂ  uctuation in day 3 FSH levels 
make OR estimation difﬁ  cult (Perloe et al. 2000). 
Since lower day 3 FSH levels represent satisfactory 
ovarian reserve and higher levels represent declin-
ing OR, a single day 3 FSH measurement may not 
be very accurate. It may be better to look at sub-
sequent cycle day 3 FSH levels (Perloe et al. 2000). 
Additionally, an increased day 3 FSH level is con-
sidered a late indicator of marked decreased fertil-
ity potential (Sharara et al. 1998). It may be better 
to look for an early indicator of declining OR and/
or decreased fertility potential.
Estradiol
Day 3 estradiol has been assessed for OR testing 
as well, but is not as extensively relied upon. Estra-
diol is a product of the granulosa cells and can be 
considered a reﬂ  ection of follicular activity. As 
with FSH, estradiol testing is also available on 
multiple automated platforms and thus is relatively 
fast, inexpensive and reproducible. However, it is 
never used alone as a biomarker for OR.
An increased estradiol level early in the men-
strual cycle suggests that follicular development 
is in an advanced stage that is inappropriate for 
day 3 (Perloe et al. 2000). However, estradiol lev-
els can be increased for two very different reasons. 
Estradiol levels can become elevated due to the 
occurrence of rapid folliculogenesis. Alternatively, 
an increased estradiol level can be due to an 
enhanced OR, such as in women afﬂ  icted with 
polycystic ovarian syndrome (PCOS), where a 
small amount of estradiol is being produced by a 
large number of antral follicles (Toner, 2003).
FSH:LH ratio
The literature gives some honorable mention to 
looking at the ratio of measured FSH to LH, which 
is most frequently determined on day 3 of the cycle. 
An elevated or exaggerated FSH:LH ratio can be 
a signal of diminished OR (Toner, 2003). By look-
ing at the ratio an elevation can be detected, even 
with an FSH level that appears to be within the 265
Ovarian reserve biomarkers
Biomarker Insights 2008:3 
reference interval (Toner, 2003). Since FSH begins 
rising before LH as OR diminishes, using two 
measurements may be more reliable and will catch 
a small increase in FSH faster (Perloe et al. 2000). 
The FSH:LH ratio is an early indicator of ovarian 
ageing and could be the ﬁ  rst of diminished OR 
(Mukherjee et al. 1996).
Direct Measures
Inhibin B
Inhibin B is a peptide hormone that is a member 
of the transforming growth factor-β (TGF-β) 
superfamily (Perloe et al. 2000). It is produced 
from small antral follicles and selectively inhibits 
FSH release (Perloe et al. 2000; Broekmans et al. 
1998). Inhibin B levels during the early follicular 
phase decrease prior to the increase in FSH levels 
(Toner, 2003). As the follicle cohort size is 
decreased, which is expected as women age, a 
decrease in inhibin B levels will be observed 
(Broekmans et al. 1998).
Unfortunately, documentation in the literature 
is minimal and also variable. Inhibin B levels do 
hold promise, but need more study and validation 
(Sharara et al. 1998). This could be attributed to a 
variation between assays used and there may be 
concerns about cycle-to-cycle variability (Sharara 
et al. 1998). One study of interest found inhibin B 
to have the best positive association with the num-
ber of oocytes collected from patients undergoing 
gonadotropin ovarian stimulation tests to assess 
ovarian reserve (Muttukrishna et al. 2005). This 
study looked at 108 women and the change in 
inhibin B between days 3 and 4, as well as other 
biomarkers. Currently, there is only one commer-
cially available assay for inhibin B. Unfortunately, 
it is still being optimized and is currently available 
for research use only.
AMH
Like inhibin B, antimüllerian hormone (AMH) is 
also a member of the TGF-β superfamily. AMH is 
produced by the granulosa cells of pre-antral and 
small antral follicles. Follicular growth is modu-
lated by AMH, which inhibits recruitment of fol-
licles from the primordial pool by modifying the 
FSH sensitivity of those follicles (La Marca et al. 
2006; Visser et al. 2006). AMH is considered to be 
reﬂ  ective of the non-FSH dependant follicular 
growth. As a follicle matures, AMH production 
disappears allowing the follicle to complete the 
development process during the FSH-dependant 
stages of growth (Visser et al. 2006). There is a 
linear decline of AMH levels over time (Visser 
et al. 2006; La Marca and Volpe, 2006). This 
decline is attributed to a decreasing number of 
follicles in the primordial pool.
AMH will in all probability become the hor-
mone of choice for assessing OR. It has been sug-
gested that AMH is the single best predictor of poor 
response for ART (Muttukrishna et al. 2005). The 
fact that AMH is secreted without dependence on 
other hormones, particularly the gonadotropins, 
and that AMH is expressed at a constant level, 
independent of cycle day make AMH very attrac-
tive as a direct measurement of OR (La Marca et al. 
2006; Feyereisen et al. 2006; Hehenkamp et al. 
2006; La Marca et al. 2007). The freedom that 
AMH testing offers both clinicians and patients by 
allowing collections to be performed on any day 
during the menstrual cycle is a vast logistical 
advantage over other biomarkers.
One recent study demonstrated not only a strong 
relationship between AMH and AFC, but that this 
relationship was stronger than the other typical 
biomarkers relationships with AFC (Feyereisen 
et al. 2006). In addition to being a good biomarker 
for the quantity of follicles, another study illus-
trated that AMH is also suggestive of the quality 
of the remaining oocytes (Ebner et al. 2006). 
Women with normal reproductive performance 
were examined twice within an average of four 
years and assessed the AFC and various endocrine 
markers, demonstrating that serum AMH, followed 
by the AFC showed the most consistent correlation 
to the age-related decline of reproductive capacity 
(van Rooij et al. 2005).
Additional research is needed to recognize all 
the roles AMH plays. It will be important to rec-
ognize the mechanisms that control production of 
AMH within the granulosa cells (Feyereisen et al. 
2006). To better understand if AMH is truly reﬂ  ec-
tive of quality of the follicles, the fate of oocytes 
and embryos from individual follicles will need to 
be assessed (Feyereisen et al. 2006).
Clomiphene citrate challenge test
It is thought by some that provocative or stimula-
tion tests for ovarian reserve testing are more 
sensitive indicators than basal testing alone (Toner, 266
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2003). The Clomiphene Citrate Challenge Test 
(CCCT) is perhaps the most widely used of the 
stimulation tests for ovarian reserve. The underly-
ing assumption for this test to work is that in a 
woman with adequate ovarian reserve, there is a 
healthy developing follicle cohort that should be 
able to produce enough inhibin and estradiol to 
suppress FSH and resist the clomiphene citrate 
stress on the hypothalamus-pituitary-gonadal axis 
(Perloe et al. 2000).
The CCCT requires a baseline measurement of 
FSH on day 3 of the cycle, administration of 
100 mg of clomiphene citrate daily on cycle days 
5 through 9 and an additional measurement of FSH 
on cycle day 10. If the FSH determination on day 
10 is high, this result is suggestive of a diminished 
OR. In fact, some users of the CCCT look at both 
day 3 and day 10 FSH levels independently and 
others additively. If either or both measurements 
are high, these results are also indicative of a 
diminished OR (Perloe et al. 2000; Toner, 2003; 
Hendriks et al. 2005). When applied in an ART 
setting, the CCCT has been proven to be a better 
predictor of OR than day 3 FSH measurement 
alone (Perloe et al. 2000).
There is additional burden placed upon the 
patient when undergoing a CCCT. The two visits 
and administration of the drug for 5 days require 
patient compliance that can affect the accuracy of 
the CCCT (Hendriks et al. 2005). These patients do 
have a vested interest, so compliance may be higher 
than in other situations; however it is still an 
unknown variable that must be considered in evalu-
ating the use of the test. In addition, there may be 
no need to perform the CCCT if there is an elevated 
day 3 FSH measured (Broekmans et al. 1998).
GAST
The Gonadotropin-releasing Hormone Agonist 
Test (GAST) is another stimulation test that is fairly 
well documented in the literature. It evaluates the 
change in estradiol levels on cycle days 2 and 3 
following a subcutaneous administration of a 
gonadotropin-releasing hormone agonist (1 mg 
leuprolide acetate) (Perloe et al. 2000). The dose 
of the agonist causes a massive, temporary release 
of FSH and LH from the pituitary, which in turn 
increases estradiol production within a 24-hour 
timeframe (Broekmans et al. 1998). A robust 
increase or ﬂ  are of estradiol in response to this 
stimulation is reﬂ  ective of recruitable follicles 
in the early follicular phase which is in turn 
representative of OR (Perloe et al. 2000; Broekmans 
et al. 1998).
Summary
a.  All tests have some beneﬁ  ts. There will always 
be a combination of markers used to get the best 
answer. The best candidate for a single biomarker 
is AMH.
b. We could recommend the need of a reference 
interval study using a “normal” population in 
addition to an infertile population. Reference 
intervals for each population should be stratiﬁ  ed 
by age and body mass index and for ART 
patients, further stratified by gonadotropin 
response, i.e. poor versus good responder.
c.  Bottom line: AMH is the focus for the future of 
ovarian reserve assessment. Further clinical 
studies are needed, but today, AMH appears to 
be representative of the hands of the biological 
clock that we have been hearing tick for years.
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